MEI Pharma Price Target Increased to $15.00 by Analysts at Stifel Nicolaus (MEIP)
Analysts at Stifel Nicolaus upped their price target on shares of MEI Pharma (NASDAQ:MEIP) from $11.00 to $15.00 in a research report issued to clients and investors on Tuesday, American Banking News reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 46.91% from the stock’s previous close.
Shares of MEI Pharma (NASDAQ:MEIP) opened at 10.21 on Tuesday. MEI Pharma has a 52-week low of $2.10 and a 52-week high of $13.20. The stock’s 50-day moving average is $9.29 and its 200-day moving average is $8.21. The company’s market cap is $174.8 million.
Separately, analysts at Roth Capital raised their price target on shares of MEI Pharma from $16.00 to $20.00 in a research note to investors on Monday. They now have a “buy” rating on the stock.
MEI Pharma, Inc, formerly Marshall Edwards, Inc, is a development-stage oncology company. The Company is engaged in the development of drugs for the treatment of cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.